These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17273155)

  • 1. Hypertension and fatty liver: guilty by association?
    Brookes MJ; Cooper BT
    J Hum Hypertens; 2007 Apr; 21(4):264-70. PubMed ID: 17273155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
    Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.
    Tarantino G; Saldalamacchia G; Conca P; Arena A
    J Gastroenterol Hepatol; 2007 Mar; 22(3):293-303. PubMed ID: 17295757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic steatohepatitis and metabolic syndrome.
    Machado M; Cortez-Pinto H
    Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):637-42. PubMed ID: 16912563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent concepts in non-alcoholic fatty liver disease.
    Adams LA; Angulo P
    Diabet Med; 2005 Sep; 22(9):1129-33. PubMed ID: 16108837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease.
    Adams LA; Angulo P; Lindor KD
    CMAJ; 2005 Mar; 172(7):899-905. PubMed ID: 15795412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease: defining a common problem.
    Gasbarrini G; Vero V; Miele L; Forgione A; Hernandez AP; Greco AV; Gasbarrini A; Grieco A
    Eur Rev Med Pharmacol Sci; 2005; 9(5):253-9. PubMed ID: 16231586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome and NASH.
    Marchesini G; Marzocchi R
    Clin Liver Dis; 2007 Feb; 11(1):105-17, ix. PubMed ID: 17544974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease.
    Angulo P
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():52-6. PubMed ID: 17471859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response.
    Younossi ZM; McCullough AJ
    Liver Int; 2009 Mar; 29 Suppl 2():3-12. PubMed ID: 19187068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
    Federico A; Trappoliere M; Loguercio C
    Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for pure steatosis in alcoholic patients.
    Naveau S; Thaury J; Barri-Ova N; Balian A; Dauvois B; Njiké-Nakseu M; Prévot S; Agostini H; Perlemuter G
    Alcohol Clin Exp Res; 2009 Jun; 33(6):1104-10. PubMed ID: 19382900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the lipogenic pathway in the development of hepatic steatosis.
    Postic C; Girard J
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):643-8. PubMed ID: 19195625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease.
    Bayard M; Holt J; Boroughs E
    Am Fam Physician; 2006 Jun; 73(11):1961-8. PubMed ID: 16770927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should we manage patients with non-alcoholic fatty liver disease in 2007?
    Chan HL; de Silva HJ; Leung NW; Lim SG; Farrell GC;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):801-8. PubMed ID: 17565632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease: the mist gradually clears.
    de Alwis NM; Day CP
    J Hepatol; 2008; 48 Suppl 1():S104-12. PubMed ID: 18304679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
    Schindhelm RK; Diamant M; Dekker JM; Tushuizen ME; Teerlink T; Heine RJ
    Diabetes Metab Res Rev; 2006; 22(6):437-43. PubMed ID: 16832839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and laboratory diagnosis of the metabolic syndrome.
    Olufadi R; Byrne CD
    J Clin Pathol; 2008 Jun; 61(6):697-706. PubMed ID: 18505888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.